1. Home
  2. ASPI vs ARVN Comparison

ASPI vs ARVN Comparison

Compare ASPI & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ASP Isotopes Inc.

ASPI

ASP Isotopes Inc.

HOLD

Current Price

$4.92

Market Cap

637.1M

Sector

Industrials

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$9.83

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASPI
ARVN
Founded
2021
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
637.1M
658.2M
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
ASPI
ARVN
Price
$4.92
$9.83
Analyst Decision
Strong Buy
Buy
Analyst Count
2
19
Target Price
$12.00
$15.05
AVG Volume (30 Days)
4.0M
721.1K
Earning Date
04-10-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
$23,849,000.00
$262,600,000.00
Revenue This Year
$68.41
N/A
Revenue Next Year
$126.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
475.48
N/A
52 Week Low
$3.92
$5.90
52 Week High
$14.49
$14.22

Technical Indicators

Market Signals
Indicator
ASPI
ARVN
Relative Strength Index (RSI) 47.63 31.70
Support Level $3.98 $9.02
Resistance Level $5.90 $10.18
Average True Range (ATR) 0.51 0.41
MACD 0.04 -0.04
Stochastic Oscillator 43.38 2.60

Price Performance

Historical Comparison
ASPI
ARVN

About ASPI ASP Isotopes Inc.

ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: